ABSTRACT: Neutrophil surface molecules function in part as biological sensors. Surface antigens undergo several changes during neutrophilic maturation to accommodate the cell's function. Surface antigens may appear with neutrophilic maturation, such as CD16b, CD35, and CD10; disappear with maturation, such as CD49d and CD64; be maintained during maturation, such as CD32, CD59, and CD82; or disappear with maturation but reappear after neutrophilic extravasation, such as CD49b. This article reviews the alterations in surface antigen expression during normal neutrophilic granulopoiesis.
INTRODUCTION
Segmented neutrophils were first described by Paul Ehrlich, who was able to utilize staining techniques to identify their morphology and their granules (1) . Neutrophils are normally formed in the bone marrow from a progenitor cell, colonyforming units granulocyte-macrophage (CFU-GM). Morphologic maturation stages of neutrophils include myeloblasts, promyelocytes, myelocytes, metamyelocytes, bands, and finally segmented neutrophils. The function of a neutrophil as a member of the body defense system relies on its capability of sensing changes in the surrounding environment and reacting to these changes. Some of the surface antigens function as these biological sensors. This is why neutrophilic maturation is accompanied by surface changes to allow for the optimal performance of these functions. Surface marker abnormalities may indicate the presence of serious granulocytic disorders and could be used to establish the diagnosis of these disorders (2) (3) (4) (5) . Flow cytometry is commonly used to study surface antigens. However, three critical variables need to be considered for the appropriate interpretation of flow cytometry data pertaining to granulocytes.
Cell preparation methodology is an important factor in analysis. Several neutrophilic antigens, such as CD10, CD11b, CD13, and CD16, have large intracellular storage pools. Density gradient (DG) separation can mobilize these antigens from their intracellular location and increase their surface expression (6, 7) . Moreover, cell pre-incubation at 37 o C may affect the expression of CD35 while neutrophil suspension in serum-free medium may be associated with CD16 surface loss (8 -10) . Furthermore, neutrophilic apoptosis could increase the expression of some surface antigens, such as CD13, and decrease others, such as CD15 and CD16 (11) .
The sensitivity of different antibodies and fluorescent labels can influence the results of the analysis. Different antibodies within the same CD cluster identify different epitopes and may display different sensitivities. Phycoerythrin (PE)-labeled antibodies may be more sensitive and may identify weak expression of some antigens, such as CD13, CD14, and CD33 on neutrophils compared to other fluorescent labels (12, 13) .
The purity of neutrophilic gate is important to make judgements on highly purified populations. Monocytes and eosinophils do not express all neutrophilic markers, such as CD10 and CD16.
Neutrophilic gate should be set to minimize such contamination (3) .
With these variations, it is not surprising that major references provide information that are not consistent in their schemes of granulocyte surface antigen maturation schemes (14) . This review is intended to provide an overview of surface antigen changes with neutrophilic maturation. A summary of antigen expression during the different developmental stages of neutrophils is shown in Table 1 .
CD10
CD10 (common acute lymphoblastic leukemia antigen, CALLA, neutral endopeptidase, NEP, enkephalinase) is a 100-kDa transmembrane glycoprotein that is encoded by a gene on the long arm of chromosome 3 (15) . It has the function of zinc-binding metalloprotease, which hydrolyzes a variety of biological substances, such as bradykinin, enkephalins, and substance P (16) . CD10 is expressed on nonhematopoietic tissues, such as brush border of renal and gut epithelium, bone marrow (BM) stromal cells, and fibroblasts. In hematopoietic cells, CD10 is expressed on early B and T lymphoid precursors. However, CD10 surface expression on neutrophilic granulocytes is limited to the segmentation stage (16 -18) . An intracellular storage pool of CD10 is present on the membrane of the neutrophilic secretory granules and hence its surface expression increases with cell activators, such as 
Note. CFU-GM, colony-forming unit, granulocyte-macrophage; Promyelo, promyelocyte; Myelo, myelocyte; Metamyelo, metamyelocyte; Seg, segmented neutrophil. ϩϩϩ, strong expression; ϩϩ, moderate expression; ϩ, weak expression; Ϫ, no expression.
granulocyte-monocyte colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF), and human C5a or with DG separation of neutrophils (7, 10, 19, 20) . On the other hand, when healthy volunteers received G-CSF, the percentage of peripheral blood (PB) CD10 ϩ neutrophils dropped from 74 to 5% (21) . Compared to adult neutrophils, newborn infants have a lower expression of CD10 on their PB neutrophils (22) . The reported percentage of CD10 ϩ granulocytes in the BM has been variable. One report suggested that 25% of BM segmented neutrophils were negative for CD10 (23) . However, this report utilized DG separation and this percentage was an approximate calculation since cell sorting showed an excellent correlation between segmentation and CD10 positivity (23) . Another report indicated a much higher percentage of CD10 ϩ granulocytes in the BM that markedly exceeded the visual count of segmented neutrophils (24) . Our own study showed a close correlation between the percentage of segmented neutrophils obtained by microscopic examination of the bone marrow and the percentage of CD10 ϩ cells within the granulocyte gate using lysed whole blood technique (25) .
CD11
Integrins are a large family of cell surface ␣␤ heterodimers involved in cell-cell and cell-extracellular matrix interactions. The ␤ 2 -integrin (CD18) heterodimerizes with four distinct ␣-subunits: CD11a, CD11b, CD11c, and the recently discovered CD11d (26, 27) . The four ␣-subunits are encoded by genes on the short arm of chromosome 16 (15, 26) .
CD11a (lymphocyte function antigen-1, LFA-1, integrin ␣L subunit). This antigen has a molecular weight (MW) of approximately 180 kDa. CD11a is expressed by all leukocytes and is not expressed by platelets and nonhematopoietic tissues. Within the myeloid lineage, this antigen is moderately expressed on CFU-GM. Its expression decreases during the intermediate stages of maturation followed by increased expression at the post-mitotic stages, i.e., metamyelocytes, bands and segmented neutrophils (28) . However, an earlier study suggested that CD11a had a steady moderate expression during all stages of neutrophilic maturation (29) . CD11a has virtually no intracellular storage pool (30) . Its intensity on PB neutrophils decreases following G-CSF administration to healthy recipients and also in the presence of high bilirubin (31, 32) .
CD11b (complement receptor 3, CR3, Mac-1, integrin ␣M subunit). The MW of CD11b is approximately 170 kDa. CD11b is expressed by myeloid and NK cells. This antigen is not expressed on CFU-GM, blasts or promyelocytes. It is expressed on myelocytes and is well maintained during further maturation stages (18, 29, 33, 34) . CD11b has an intracellular storage pool in the membranes of the secretory, gelatinase, and specific granules (20) . Neonates, elderly individuals, and pregnant women have a higher level of CD11b expression on PB granulocytes (35) (36) (37) . Similar findings have been reported with G-CSF administration to healthy volunteers (38) . This antigen is not expressed at the early stages of neutrophilic maturation but is detected at the myelocytic stage and is maintained throughout further maturation stages (29, 30) .
CD11d (integrin ␣D subunit).
This antigen is approximately 150 kDa in MW. It is moderately expressed on myelomonocytic cell lines, PB leukocytes, and specialized tissue macrophages (27) . Differentiation of myelomonocytic cell lines by phorbol esters results in the downregulation of CD11d expression (39) . Its exact expression in relationship to the stages of granulocytic maturation is still undetermined.
CD13
CD13 (aminopeptidase N, gp 150) is a member of a group of membrane metalloproteases, which include CD10, CD26, and CD73. It has a MW of 150 -170 kDa and is encoded by a gene on the long arm of chromosome 15 (15) . CD13 plays a role in cell surface antigen presentation and preferentially cleaves neutral amino acids. CD13 is expressed by nonhematopoietic cells, such as epithelial tissue, endothelial cells, fibroblasts, and brain cells (40) . This antigen is strongly expressed on PB monocytes with a weaker expression on PB neutrophils (12, 41) . It was reported on approximately 5% of BM mononuclear cells (41) . CFU-GM are positive for CD13 (42, 43) . Some studies have considered CD13 as an immature marker that disappeared with granulocytic maturation, particularly following the surface expression of CD66 (44, 45) . These studies have utilized fluorescein isothiocyanate (FITC)-labeled antibodies. However, PE-labeled antibodies showed a more consistent expression of CD13 on PB granulocytes (12) . Moreover, our own study and others suggest that CD13 actually increases with terminal differentiation, particularly following the appearance of CD16 (5, 25) . Because of the presence of intracellular storage pool in the secretory granules, CD13 surface expression increases with activation or DG separation (6, 7, 10) . Surface expression of CD13 also increases with apoptosis (11) . With these controversial results, we elected no to include CD13 in Table 1 .
CD15, CD15s, and CD15u
CD15 antibodies recognize the trisaccharide antigen 3-fucosyl-N-acetyllactosamine, also referred to as Lewis x or X-hapten (46) . This antigen is generated by the fucolysation of the distal lactosamine unit of the type 2 chain structure through ␣ 1,3-fucosyl transferase (FUT). The CD15s (sialylated CD15, sialyl Lewis x ) is formed by sialylation of the distal lactosamine unit prior to fucolysation (47) . A sulfated CD15 (CD15u) has been recently recognized at the 7th Human Leukocyte Differentiation Antigen Workshop (48) . CD15 and CD15s are not specific for hematopoietic cells since the former is expressed on embryonic tissues and adenocarcinomas while the latter is expressed on high-endothelium venules and subcapsular sinuses of lymph nodes. The expression of CD15 and CD15s during granulopoiesis has been debated. In granulocyte maturation charts, CD15 has been marked as being expressed on CFU-GM through the segmentation phase of neutrophils (14) . Other studies indicated the expression of CD15 at the blast stage and its absence on CD34 ϩ cells (18, 33, 34) . When BM cells were purged using anti-CD15 antibody for autologous BM transplantation, successful engraftment with subsequent normal granulopoiesis was reported (49) . More recent studies indicate that only a small portion of bone marrow precursor cells (CD34 ϩ or CD117 ϩ ) expresses CD15 to the extent of using the phenotype CD15 ϩ /CD117
ϩ as a leukemic phenotype to monitor minimal residual disease (42, 50) . On the other hand, CD15s has been consistently expressed on CD34 ϩ cells (28, 51) . It is known that anti-CD15 antibodies do not react with CD15s unless the sialic acid is removed (46) . This fact has been confirmed on monocytes in which CD15s is the predominant form since monocytes react with anti-CD15 antibodies only after neuraminidase digestion (13, 52) . Experiments with leukemic blasts and HL-60 cell line indicated that blasts were negative for CD15 and weakly positive for CD15s and the expression of both CD15 forms increased significantly with induced maturation from promyelocytes to segmented neutrophils (53, 54) . When normal marrows were studied, CD15 was weakly expressed on blasts and strongly expressed on more mature granulocytic cells from promyelocytes onwards with only slight decrease at the segmentation phase (33) . A similar study of normal marrow confirmed the expression of CD15s on CD34 ϩ cells following the expression of CD13/CD33 (28). CD15s expression was high at the blast, promyelocyte and myelocyte stages. CD15s expression was downregulated then was upregulated with terminal differentiation (28) . CD15 has an intracellular pool in the membranes of the primary and secondary granules, and surface expression is increased upon stimulation with chemotactic peptides (46, 55) . CD15s is increased on PB neutrophils with G-CSF administration (56) . CD15 expression on PB neutrophils is decreased with increased serum bilirubin and in healthy donors receiving G-CSF (21, 32). Its expression is also decreased with apoptosis (11).
CD16b
CD16 (Fc␥ receptor III) is comprised of two forms: a transmembrane form (CD16a), which is present on NK cells, macrophages and mast cells, and a glycosylphosphatidyl inositol (GPI)-linked form (CD16b), which is expressed on neutrophils (15) . CD16 has a MW of 50 -80 kDa and it functions as a low affinity receptor for IgG. It is encoded by a gene on the long arm of chromosome 1. CD16 appears late during neutrophilic maturation. Several studies indicate its appearance at the metamyelocytes stage with the highest expression at the band and segmented stages of neutrophilic development (28, 33, 57) . Other studies suggested that CD16 is expressed at the band stage (58, 59) . However, one of these studies (59) was performed on patients with known inflammatory or infectious processes. CD16 is known to show abnormally low expression under these circumstances (60, 61) . Intracytoplasmic storage pool for CD16 has been identified on the membranes of secretory granules (20) . When separated by DG or incubated in serum and activated by C5a, neutrophils show increase in the surface expression of CD16 (7, 10) . However, when neutrophils are washed before incubation, these is shedding and loss of their surface CD16 (9, 10). Healthy volunteers receiving G-CSF have shown decreased intensity of CD16 expression on their neutrophils (21) . Compared to adults, premature infants and neonates have markedly decreased levels of CD16 expression on their PB neutrophils (62, 63) . CD16 is also decreased on the surface of apoptotic neutrophils (11) .
CD18
CD18 (integrin ␤ 2 subunit) is a 95-kDa polypeptide. It is expressed on all leukocytes forming a heterodimer with members of the CD11 group. It is encoded by a gene on the long arm of chromosome 21 (15) . The expression of CD18 during granulocytic maturation shows several fluctuations. CFU-GM and blast cells express moderate amounts of CD18. This is followed by downregulation at the promyelocyte stage and upregulation to maximum expression at the my- (28) . PB neutrophils in the elderly express higher levels of CD18 compared to other groups (64) . G-CSF administration enhances the expression of CD18 on PB granulocytes (38) .
CD24
CD24 (heat-stable antigen, HSA, BA-1) is a GPI-linked sialoglycoprotein that is predicted to be only 33 amino acids long (15) . It is encoded by a gene on the long arm of chromosome 6. This antigen seems to be involved in signal transduction (15) . It is expressed by B lymphocytes, normal epithelium, and some carcinomas. CD24 is not expressed on normal monocytes although anomalously expressed in acute monocytic leukemia (15, 65) . More than 95% of PB neutrophils are CD24
ϩ (66, 67) . Initial anecdotal evidence suggested that CD24 began to be expressed at the myelocyte stage (66, 67) . Our recent study has confirmed that this antigen is expressed at the myelocytic stage of development and is maintained throughout the more mature stages (68) .
CD29
CD29 (integrin ␤ 1 subunit) has a MW of 130 kDa and is encoded by a gene on the short arm of chromosome 10. It heterodimerizes with ␣ subunits to form CD49 (15) . It is expressed on all leukocytes. This antigen is highly expressed on CD34 ϩ cells and intermediately expressed on blasts, promyelocytes, and myelocytes. Metamyelocytes, bands and segmented neutrophils have low levels of expression (28) .
CD31
CD31 (platelet endothelial cell adhesion molecule 1, PECAM-1, GPIIa) has a MW of approximately 135 kDa and its gene is located on the long arm of chromosome 17. It binds homotypically to other CD31 antigens and heterotypically with glycosaminoglycans (15) . Its expression is limited to endothelial cells, platelets and leukocytes. CD31 is highly expressed on CD34 ϩ cells and intermediately expressed on blasts, promyelo- (28) . The expression of CD31 on neutrophils is further downregulated with apoptosis (11).
CD32
CD32 (Fc␥ receptor II) is a low-affinity Fc␥ receptor that binds only to polymeric or aggregated IgG (15) . Its MW is approximately 40 kDa and is encoded by possibly three genes on the long arm of chromosome 1. CD32 is expressed on leukocytes, platelets, and placental endothelial cells. This antigen is expressed on the CFU-GM and is maintained throughout granulocytic maturation including segmented neutrophils (69) . The administration of G-CSF to healthy volunteers has been associated with enhanced expression of CD32 on PB neutrophils (38) . Neonatal granulocytes express higher levels of CD32 compared to adults (62) . The expression of this antigen is decreased on apoptotic neutrophils but is not affected by DG separation (7, 11) .
CD33
CD33 (gp 67) has a MW of 67 kDa and its gene is locates on the long arm of chromosome 19. This antigen may mediate cell-cell adhesion. It is restricted to hematopoietic cells and is normally expressed by monocytic and myeloid lineages. It is normally expressed at high levels on monocytes, myeloid progenitors (CFU-GM and CD34 ϩ cells), myeloblasts, promyelocytes, and myelocytes (42, 43, 70, 71) . Although CD33 has been reported to be absent beyond the myelocytic stage, studies using more sensitive PE-labeled antibodies reported low expression of CD33 on neutrophils beyond the myelocytic stage (12, 34) .
CD35
CD35 (complement receptor 1, CR1, C3b, and C4b receptor, immune adherence receptor) is a single chain antigen of MW of 190-285 kDa, which is encoded by a gene on the long arm of chromosome 1 (15) . It is expressed on erythrocytes, leukocytes, follicular dendritic cells, and kidney glomerular podocytes. On granulocytes, this antigen is late appearing being expressed at the band and segmented stages of neutrophil development (72). CD35 has a large intracytoplasmic storage pool in the membranes of the secretory granules (20) . During the resting phase, only 5 to 10% of the total cellular CD35 is expressed on the plasma membrane (72). However, when neutrophils are activated in-vitro or by administering G-CSF to healthy volunteers, the expression of CD35 markedly increases (8, 38) . CD35 expression on neonatal granulocytes is much higher than adult granulocytes (73) . Apoptotic neutrophils downregulate this antigen (11) .
CD44
CD44 (lymphocyte homing receptor, phagocytic glycoprotein 1, Pgp-1, homing-associated cell adhesion molecule, H-CAM) has several isoforms that vary in MW from 80 to 250 kDa and is encoded by a gene on the short arm of chromosome 11 (15) . It is widely expressed on hematopoietic and nonhematopoietic cells, including epithelial, mesothelial, and endothelial cells. CD44H is the major isoform expressed on hematopoietic cells. CD44 is involved in cell adhesion to extracellular matrix, particularly hyaluronate, cell differentiation, and inflammatory response (74) . CD44 is strongly expressed on CD34 ϩ cells. It is markedly downregulated with granulocytic differentiation and is upregulated with further terminal differentiation of neutrophils (28, 29, 75) .
CD45 and CD45 Isoforms
CD45 (leukocyte common antigen, LCA, T200) is composed of a series of glycoproteins that are found on all nucleated hematopoietic cells. Its MW ranges from 180 to 220 kDa and the encoding gene has been located on the long arm of chromosome 1. CD45 has been identified as tyrosine phosphatase (76) . CD45 is expressed early during granulopoiesis and persist throughout granulocytic differentiation. One study, using DG separation of granulocytes, indicated no change in the intensity of CD45 expression during granulopoiesis (18) . However, a later study indicated increased surface expression of CD45 with maturation (77) . The expression of surface CD45 on granulocytes increases with stimulation with human C5a and with DG separation (7, 10) . CD45 isoforms vary in MW from 180 to 220 kDa. During normal granulopoiesis, the high MW isoform (CD45RA, 220 kDa) is expressed at the myeloblast and promyelocyte stage and disappears with further maturation (78) , although a previous study indicated the absence of CD45RA on all stages of granulocytic maturation (18) . In addition, CD45RA is expressed on CD34 ϩ myeloid progenitor cells (43) . PB granulocytes are CD45RA negative (77) (78) (79) . Yet, despite the absence of its surface expression, immunocytochemical stains suggest the presence of a significant cytoplasmic pool of CD45RA, which became apparent at the myelocyte stage and persisted with further maturation (77) . This pool can be mobilized to the surface by the calcium ionophore A23187 (77) . The low MW isoform (CD45RO, 180 kDa) is expressed dimly at the myelocyte stage with maximum expression at the segmented neutrophil (76 -78) . Granulocyte stimulation with human C5a causes upregulation of the expression of CD45RO (10).
CD49
CD49 (very late antigen, VLA) is a member of the integrin family. The ␤ 1 -integrin subunit (CD29) heterodimerizes with six ␣ subunits: CD49a, CD49b, CD49c, CD49d, CD49e, and CD49f.
CD49a (␣1 integrin subunit, VLA-1 ␣ subunit).
It has a MW of approximately 210 kDa and it binds laminin and collagen. It is encoded by a gene on the short arm of chromosome 5. It is not expressed on granulocytes (80) .
CD49b (␣2 integrin subunit, VLA-2 ␣ subunit)
. This antigen has a MW of approximately 165 kDa and it also binds to collagen and laminin. Its gene is located on the long arm of chromosome 5. This antigen is virtually absent on neutrophils and precursors (81) . However, it is expressed on neutrophils following extravasation (80). , VLA-3 ␣ subunit) . The MW of CD49c is approximately 155 kDa and its gene is located on the long arm of chromosome 17. This antigen binds to fibronectin in addition to laminin and collagen. This antigen is virtually absent on neutrophils and precursors (80, 81) .
CD49c (␣3 integrin subunit

CD49d (␣4 integrin subunit, VLA-4 ␣ subunit).
This antigen binds CD106 (VCAM-1) and fibronectin and has a MW of 150 -180 kDa. Its gene is located on the long arm of chromosome 2. It is expressed by most leukocytes and nonhematopoietic cells, such as Kupffer cells and muscle cells. CD49d is expressed on CFU-GM and a high level of expression is maintained until the myelocytic stage. CD49d expression sharply declines at the metamyelocyte stage and is virtually absent on band and segmented neutrophils (28, 81) . Pregnancy induces no changes of its expression on PB neutrophils (37) .
CD49e (␣5 integrin subunit, VLA-5 ␣ subunit).
It has a MW of approximately 155 kDa and acts as fibronectin receptor. It is encoded by a gene on the long arm of chromosome 12. It is highly expressed on CD34 ϩ cells and intermediately expressed on blasts, promyelocytes, and myelocytes. Metamyelocytes, bands and segmented neutrophils have low levels of expression (28) .
CD49f (␣6 integrin subunit, VLA-6 ␣ subunit)
. This antigen has a MW of 155 kDa and functions as laminin receptor. Its gene is mapped to the long arm of chromosome 2. This antigen is virtually absent on neutrophils and precursors (81) .
CD54
CD54 (intercellular adhesion molecule-1, ICAM-1) has a MW of 90 -110 kDa and is encoded by a gene on the short arm of chromosome 19. CD54 has a wide tissue distribution on hematopoietic cells and nonhematopoietic cells, including endothelial cells. This antigen is a ligand for the leukocyte LFA-1 and contributes to the extravasation of leukocytes, particularly in areas of (15) . During granulopoiesis, CD54 is expressed on CFU-GM but its expression is downregulated with granulocytic maturation. Myeloblasts and promyelocytes express CD54. However, differentiation beyond the promyelocyte stage is associated with very weak to absent expression (83, 84) . In vitro activation of granulocytes or administration of G-CSF to healthy individuals is associated with significantly enhanced expression on neutrophils (84, 85) . DG separation has no effect on CD54 expression on neutrophils (7).
CD55
CD55 (complement decay accelerating factor, DAF) is a GPI-linked complement regulatory protein that is expressed by all cells in contact with plasma, including hematopoietic cells and a wide variety of nonhematopoietic cells. It accelerates the decay of C4b2a (C3-convertase of the classical pathway) and C3bBb (the C3-convertase of the alternative pathway). It has a MW of 55-70 kDa and its gene is located on the long arm of chromosome 1. This antigen is expressed on CD34 ϩ BM cells. Further development of granulocytes is accompanied by decreased expression until the stage of metamyelocytes where its expression increases and is then maintained throughout the remaining maturational stages (86) . Resting neonatal neutrophils express a higher level of CD55 compared to adults (73) .
CD59
CD59 (complement protectin, membrane inhibitor of reactive lysis, MIRL, P-18) is membrane-associated complement regulatory protein that is anchored to cell membrane by GPI. This antigen hinders the cytolytic activity of homologous complement by blocking the assembly of membrane attack complex. It is expressed by all blood cells that are in contact with plasma complement proteins and it is also expressed by a wide spectrum of nonhematopoietic cells (15) . It has a MW of 18 -25 kDa and its gene is located on the short arm of chromosome 11. This antigen is expressed on CD34 ϩ cells and its expression is well maintained during all stages of granulocytic maturation (86) . Adult neutrophils have a higher CD59 expression than neonatal neutrophils (73) . When neutrophils are activated with N-formylmethionyl-phenylalanine (fMLP), surface expression of CD59 is increased (73) .
CD62
CD62 is encoded by a gene on the long arm of chromosome 1 (15) . It includes the following.
CD62E (E-selectin, ELAM).
This antigen is expressed on endothelial cells at the sites of inflammation and is not expressed on leukocytes (15) .
CD62L (L-selectin, LECAM, LAM-1, leu-8, MEL-14 antigen).
Like other selectins, this antigen mediates the initial tethering and rolling of leukocytes on endothelial surfaces and can also mediate neutrophil-neutrophil interaction through the recognition of CD162 (15) . It has a MW of 74 and 95 kDa. This antigen is normally expressed on PB monocytes, lymphocytes, and granulocytes, with basophils expressing the highest level of expression (12) . CD34 ϩ cells express CD62L, which is maintained throughout granulopoiesis and monopoiesis, while it is lost during the very early stages of erythroid differentiation (29, 43) . CD62L is shed and lost from cell surface of neutrophils with activation, apoptosis, and with in vivo administration of G-CSF (56, 87, 88) . Normal pregnancy has no effect on the expression of CD62L on PB neutrophils (37) while increased serum bilirubin has been associated with decreased expression (32) . Fetal neutrophils have the same expression of CD62L as adults. However, term and premature neonates have lower expression of this antigen (36, 89) . DG separation has no effect on surface expression of this antigen (7).
CD62P (P-selectin, PADGEM, GMP-140).
It is expressed by megakaryocytes, activated platelets, and activated endothelial cells and is not expressed on leukocytes (15) .
CD64
CD64 (Fc␥ receptor I) is a high-affinity Fc␥ receptor, which binds monomeric as well as aggregated IgG (15) . It has a MW of 72 kDa and it encoded by three genes (A, B, and C) on the long arm of chromosome 1. The majority of CFU-GM expresses CD64 (90) . Its expression is maintained during granulopoiesis up to the level of neutrophilic metamyelocytes (91) . Normal band and segmented neutrophils do not express CD64 (57, 69, 91) . However, healthy African individuals show the presence of CD64 ϩ neutrophils in their PB (92) . When healthy volunteers were given G-CSF or their CD34 ϩ cells were cultured in presence of G-CSF, CD64 was expressed on segmented neutrophils (38, 91) . Centenarians have increased CD64
ϩ neutrophils, which may be related to a higher level of interferon (IFN) ␥, a known inducer of CD64 expression (93) . A similar phenomenon has been reported in normal pregnancy (37) . On the other hand, neonatal granulocytes express lower levels of CD64 compared to adult granulocytes (62) .
CD65 and CD65S
CD65 is a fucosylated carbohydrate that shares common structure with CD15 and CD15s (47) . This antigen results the fucosylation of the inner lactosamine unit of ␣2,3 sialylated polylactosamine by ␣1,3 FUT enzyme (47, 53) . Its sialylated form is designated CD65s, which is recognized by the commonly used antibody VIM-2. It is expressed on neutrophils in addition to nonhematopoietic cells, such as secretory pancreas and bronchial epithelium (40) . Only a small percentage of CD34 ϩ cells normally express CD65 to the extent that this antigen was considered to be ideal to purge abnormal progenitor cells from patients with acute myeloid leukemia (43, 94) . HL 60 cell lines strongly express this antigen. When this cell line is induced to differentiate using dimethyl sulfoxide (DMSO), CD65 is progressively lost (53) . However, in normal marrow, CD65 begins to appear with early commitment to the myeloid lineage and gradually increases in the intensity of expression until it is strongly expressed on mature neutrophils (40, 53, 95) .
CD66
The carcinoembryonic antigen family (CEA, CD66a-CD66e) is a family of closely related glycoproteins that are encoded by a dense cluster of genes mapped to the long arm of chromosome 19 (15) . CD66 molecules can mediate cell-cell interaction and these molecules exhibit rapid upregulation following activation.
CD66a (biliary glycoprotein, BGP, NCA-160).
This antigen has a MW of 160 -180 kDa and is expressed on granulocytes, T cells, and a subpopulation of activated NK cells (15) . In addition, CD66a has a wide tissue distribution, such as the epithelia of esophagus, kidney, and biliary system. It is reported to stain myelocytes and more mature granulocytes (96) . Monocytes are usually negative but some tissue macrophages may express CD66a (40, 45). The major intracellular storage component is located in the secondary granules of neutrophils (97) .
CD66b (CD67, NCA-95, CGM6
). This antigen is GPI-anchored and has a MW of 95-100 kDa. It is expressed on granulocytes and not monocytes or nonhematopoietic cells (40) . During granulopoiesis, CD66b is expressed on promyelocytes and is maintained throughout the granulocytic maturation although it is less expressed on metamyelocytes, bands and segmented neutrophils compared to earlier stages of maturation (28) . The major intracellular component is in the secondary granules of neutrophils and its surface expression is markedly upregulated with DG separation or granulocyte stimulation (7, 97) . However, neutrophilic apoptosis is associated with decreased surface expression (11) . Normal pregnancy has no effect on the surface expression of CD66b (37) . (97) . Although its expression during granulopoiesis is not clearly reported, it appears to be expressed on more mature granulocytes but not monocytes (45) .
CD66d (CGM1).
It has the lowest MW of approximately 30 kDa (15) . It is expressed on nonhematopoietic cells, such as epithelial cells. Similar to CD66c, its exact stage of expression has not been clearly studied but it is expressed on more mature granulocytes and not monocytes (45) .
CD66e (CEA).
This antigen is not expressed on hematopoietic cells.
CD82
CD82 (KAI1, C33, R2, 4F9) has a MW of approximately 50 -53 kDa and it encoded by a gene on the short arm of chromosome 11 (15) . This antigen may play a role in signal transduction and has a ubiquitous tissue distribution including cancer cells. It is expressed by monocytes and platelets with weak expression on resting lymphocytes. It is not expressed on erythrocytes. CD82 is strongly expressed on CD34 ϩ hematopoietic progenitor cells. With further granulocytic maturation, CD82 expression declines and is maintained at a moderate level through the segmented phase of neutrophils. More than 90% of PB granulocytes moderately express CD82 (98) .
CD87
CD87 (urokinase plasminogen activator receptor, uPAR, M5 antigen) is a GPI-anchored glycoprotein of approximately 35-65 kDa MW and is encoded by a gene on the long arm of chromosome 19. In addition to concentrating uPA, CD87 may play a role in the extravasation of leukocytes. CD87 is known to be expressed on the surface of granulocytes although it is not clear at what stage of granulocytic development. CD34 ϩ cells have been consistently negative for CD87 (99, 100) . The original study by Gadd et al. (101) on BM cells suggested that CD87 was expressed only during terminal differentiation. Another study using immunocytochemistry reported the expression of CD87 on myelocytes and more mature granulocytic elements (99) . However, a more recent study concluded that this antigen was expressed on all granulocytic precursors, i.e., promyelocytes, myelocytes, and metamyelocytes (100). The latter study identified granulocytic precursors using unusual antibody combinations, such as CD13, CD45, and HLA-DR. Our own study suggests that CD87 is expressed only at the band and segmented stages of neutrophilic development (102) . CD87 surface expression is downregulated with neutrophil apoptosis (11) . Neutrophilic secondary, gelatinase, and secretory granules contain extensive intracellular storage pool for CD87, which is mobilized to the cell surface upon stimulation of neutrophils with phorbol myristate acetate (PMA) or TNF (20, 103) .
CD162
CD162 (P-selectin glycoprotein ligand 1, PSGL-1) is a sialomucin of a MW of approximately 120 kDa. Its gene has been mapped to the long arm of chromosome 19 (15) . CD162 is expressed by granulocytes, lymphocytes, dendritic cells, and fallopian tube epithelium. CD162 is the major CD62P (P-selectin) ligand. This interaction mediates the tethering and rolling of cells on the endothelium, an important initial step in extravasation. CD34 ϩ cells are positive for CD162. However, it is lost with commitment to erythroid or megakaryocytic lineage (104) . This antigen is expressed on myeloid cells from the myeloblast stage to the segmented neutrophil (104) . Activation of leukocytes in vitro by platelet activating factor or PMA resulted in shedding of this antigen from the surface of these cells (105) .
